PARP1 and cancer: Indeed, the use of PARP1/2 ihibitors in cancer cells bearing DDR defects has been gaining always more attention [39], and in vitro data has shown that the treatment of TGCTs cells with PARP inhibitor olaparib are able to sensitize testicular cancer cells to cisplatin treatment, and in particular in case of cisplatinum resistance [14].